Artikel

Omalizumab for the treatment of solar urticaria: many questions remain unresolved

---

Omalizumab (Xolair®), a humanized monoclonal antibody against human immunoglobulin E (IgE), was recently approved as an add-on therapy for chronic spontaneous urticaria (csU) refractory to treatment in patients aged 12 years and above. e dose in this indication is 300 mg subcutaneously every 4 weeks. is dose was administered to pa-tients showing an inadequate response despite re peated systemic treatment with H1 and H2 antihis-tamines or leukotriene receptor antagonists. e urticaria activity score over 7 days (UAS7) in this group went down from 31.2 on average to ≤ 6 in 52 % and to 0 in 33 % within a 12-week period

---

Ketersediaan

Tidak ada salinan data

Informasi Detail

Judul Seri

-

No. Panggil

Artikel

Penerbit

: Springer., 2016

Deskripsi Fisik

-

Bahasa

English

ISBN/ISSN

DOI: 10.1007/s40629-

Klasifikasi

NONE

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

Allergo J Int 2016; 25:96–7

Subjek

Medicine
Omalizumab

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar